Monopar Therapeutics (MNPR) Common Equity (2016 - 2025)

Monopar Therapeutics (MNPR) has 10 years of Common Equity data on file, last reported at $137.8 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 150.43% year-over-year to $137.8 million; the trailing twelve-month figure through Dec 2025 stood at $137.8 million (up 150.43% YoY), and the FY2025 full-year result was $137.8 million, up 150.43% from the prior year.
• Common Equity eased to $137.8 million in Q4 2025, from $141.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $141.6 million in Q3 2025 to a low of $4.9 million in Q3 2024.
• A 5-year average of $31.5 million and a median of $15.7 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 47.28% in 2023 and soared 2761.61% in 2025, its largest moves.
• Tracing MNPR's Common Equity over 5 years: stood at $18.9 million in 2021, then slumped by 46.73% to $10.1 million in 2022, then slumped by 44.62% to $5.6 million in 2023, then jumped by 884.95% to $55.0 million in 2024, then jumped by 150.43% to $137.8 million in 2025.
• Business Quant data shows MNPR's Common Equity at $137.8 million in Q4 2025, $141.6 million in Q3 2025, and $52.2 million in Q2 2025.